CDSCO to fast-track applications, issues regulatory pathway for R & D of drugs for COVID-19
Delhi: Through a recent notice Central Drugs Standard Control Organization(CDSCO) , Directorate General of Health Services has released the regulatory pathway for R & D of drugs for COVID-19. The guidance for the same has been issued by Dr. V. G. Romani, Drugs Controller General (India) to all the Stakeholders, where the DCGI clearly stated that all applications relating to covid-19 will be processed by CDSCO on high priority.
Novel Corona-virus Disease (COVID-19) has spread over 118 countries with now more than 191,127 cases and 7807 people have lost theft lives as on 18,03.2020. World Health Organization (WHO) has declared it a pandemic.
At present, there is no current evidence from randomized clinical trials to recommend any specific treatment for suspected or confirmed patients with COVID-19. In order to encourage research & development of drug or vaccine for prevention or treatment of COVID-19, any application submitted to CDSCO will be processed on high priority. CDSCO will also provide guidance on the regulatory pathway on such matter,
The details are as under -
1. Any firm having a Drug/Vaccine under development for COVID-19 can directly approach DCG(I) through the Public Relations Office for seeking guidance for the regulatory pathways.
2. Any firm or research institute having a protocol for the repurposing of existing drugs/vaccines for the treatment of COVID-19 will also be given priority for review and approval.
3. Applications for Clinical Trial permission and applications to import or manufacture Drug/Vaccine for sale and distribution would be processed on priority though expedited review/accelerated approval.
4. Any firm having Drug/Vaccine already approved for COVID-19 in any other country can directly approach DCG(I) through Public Relations Office regarding expedited review/accelerated approval for marketing in India.
5. Data requirement for animal toxicity study, clinical study, stability study, etc. may be abbreviated, deferred, or waived on case to case basis depending upon the type of vaccine, nature of drug, plant from which the drug is extracted & its experience in case of Phyto-pharmaceuticals.
6. Applications to manufacture or import Drug/Vaccine for the test, analysis, and further use BA/BE or Clinical Trial may be processed within 7 clays.
7. in case of emergency, Import license (Form 10) would be granted without Registration Certificate (Form 41) subject to the approval of the Central Government.
For any additional information kindly contact Public Relations Office through toll-free number 1800 11 1454 & write to email@example.com
For full information click on the link mentioned below:
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here